GC Cell, a notable player in the biotechnology field, is increasingly making its mark in the area of cell and gene therapy (CGT).
Under the guidance of CEO James Park, who was appointed in March 2023, the company is actively engaged in advancing research and development within the CGT landscape.
With a strategy encompassing both innovation and expansion, GC Cell is contributing to the broader dialogue and progress in healthcare technology, developing new treatment options, and expanding its reach in the global market, highlighting the company's role in the evolving healthcare sector.
Korea Biomedical Review met with Park during the J.P. Morgan Healthcare Conference (JPMHC) 2024, held in San Francisco from last Monday to Thursday, to talk about the company's goals at the event and its strategies moving forward.
Park started the interview by sharing insightful details about the company's strategic direction and progress since his appointment last March.
"My initial focus was on understanding the various facets of the company, especially the R&D unit, which he considers crucial for GC Cell's future," he said. "The future of the company is driven by the R&D pipeline."
Park emphasized the need to shift the R&D focus from academic pursuits to commercial value, particularly in developing new platforms for CGT.
Please click on Reference link below if you wish to read the full article.